Illumina

Historical price data

Founded in 1998, Illumina's mission is to improve human health by unlocking the power of the genome. The company has achieved a dominant ~75-80% share of the global next-generation sequencing (NGS) market through its proprietary sequencing-by-synthesis technology, which delivers unparalleled accuracy, throughput, and cost-effectiveness. Its strategy revolves around expanding its technology ecosystem, driving clinical adoption, and leveraging a razor-and-blades business model with high-margin recurring consumables revenue.

Proprietary Sequencing-by-Synthesis (SBS) chemistry and integrated system architecture for next-generation DNA sequencing, enabling high-throughput, high-accuracy genomic analysis.

Dominates with ~75-80% NGS market share. Primary competitors are MGI (lower-cost alternative in China/research), Thermo Fisher (targeted sequencing niche), and PacBio/Oxford Nanopore (complementary long-read specialists). Illumina's ecosystem, accuracy, and installed base create high switching costs.